Pharmafile Logo
Pharmafocus logo
Advanced Search
rd_hands

BioMarin reports positive early-stage results for trial drug to treat CLN2 disease

March 4, 2016
Medical Communications

Biotechnology firm BioMarin Pharmaceutical has announced positive results from early stage trial for drug to treat neurodegenerative disease in children.  …

News
merck_logo_blue_rgb

Merck & Pfizer tie-up with Verastem to develop ovarian cancer drug

March 4, 2016
Medical Communications

German drug major Merck along with Pfizer has joined forces with Verastem to develop the trial drug candidate avelumab to …

News
sanofi_logo_vertical_2011_4colors

Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment

March 4, 2016
Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2

Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …

News
magic_bullets_pills

Almost half of US physicians will prescribe more biosimilars, according to survey

March 4, 2016
Medical Communications Obama, US, biosimilar, patent, prescribing

New data published by InCrowd has suggested that US physicians are very amenable to the prescription of biosimilars, with some …

News
baxalta

Baxalta seeks European marketing rights for haemophilia drug

March 3, 2016
Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta

Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …

News
ucb_logo_and_chief_executive

UCB targets regulatory filing for its osteoporosis drug in 2016

March 3, 2016
Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …

News
the_european_molecular_biology_laboratory

Merck announces drug discovery collaboration with European Molecular Biology Laboratory

March 3, 2016
Research and Development Cancer, Merck, biomarkers

Merck has announced that it has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL), that will …

News
amgen_flag

Amgen sues Novartis over Enbrel biosimilar

March 3, 2016
Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars

Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …

News
deb_jorn

Valeant company group chairman and executive vice president resigns

March 3, 2016
Medical Communications, Sales and Marketing Valeant, appointed, resignation

In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …

Appointment
gardasil_9

CHMP recommends Sanofi’s two-dose schedule HPV vaccine

March 3, 2016
Research and Development HPV vaccine, MSD, Sanofi Pasteur

Sanofi Pasteur’s and MSD’s vaccine against human papillomavirus (HPV), Gardasil 9, has received a positive opinion from the European Medicine …

News
novo_nordisk

Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment

March 2, 2016
Sales and Marketing Novo Nordisk, Xultophy, diabetes

Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …

News
nda_group_appointment

Bill Griffiths joins NDA group as general manager UK

March 2, 2016
Medical Communications NDA Group

Industry veteran Bill Griffiths has joined NDA Group to head up the company’s UK consulting team and NDA’s advisory board.  …

Appointment
gilead-sciences

FDA approves Gilead’s Odefsey for treatment of HIV-1 infection

March 2, 2016
Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …

News
janssen_latest_logo_on_sign

Janssen slams NICE decision on Imbruvica

March 2, 2016
Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …

News
humira_abbott_

Top 10 medicines issued in England by prescription cost in 2014-15

March 2, 2016
Research and Development, Sales and Marketing Cost, Humira, NHS, prescription

AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …

Feature
hilary_clinton_speaks_at_a_rally_in_des_moines_in_january

Clinton steps up attacks on Valeant in latest campaign advert

March 2, 2016
Research and Development, Sales and Marketing Hilary Clinton, Valeant

This is not the first time the pharma industry has drawn the ire of the US presidential hopefuls, but Hilary …

News

LEO Pharma UK/Ireland appoints new dermatology director

March 2, 2016
Medical Communications, Sales and Marketing

LEO Pharma has appointed Michael Hinchy as dermatology director with responsibility for its UK/Ireland affiliate. Michael brings over 16 years …

Appointment
chi_med

Chi-Med starts Phase II trial for thyroid cancer drug

March 2, 2016
Research and Development Chi-Med

Hutchison China MediTech (Chi-Med) says its unit Hutchison MediPharma (HMP) has initiated mid-stage trials for sulfatinib to treat differentiated thyroid …

News
graff_ferring

Ferring names Aaron Graff CEO of US holding company

March 2, 2016
Medical Communications

Swiss fertility treatment company Ferring Pharmaceuticals on Tuesday named Aaron Graff the chief executive of its US unit, Ferring Holding. …

Appointment
merck_innovation_centre

Merck begins late-stage trials of Humira biosimilar

March 2, 2016
Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars

Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026